Literature DB >> 26249131

Clinicopathological profile of orbital exenteration: 14 years of experience from a tertiary eye care center in South India.

Mohammad Javed Ali1, Aditi Pujari2, Tarjani Vivek Dave2, Swathi Kaliki2, Milind N Naik2.   

Abstract

This study aims to describe the clinicopathological features and outcomes of patients who underwent orbital exenteration at a tertiary eye care center in south India. Retrospective chart reviews were performed on all patients undergoing orbital exenteration from January 1999 to December 2012. Parameters recorded include demographic data, clinical presentations, past medical or surgical interventions, exenteration notes, histopathological diagnosis, adjunctive treatment, follow-up examination findings, recurrences, complications, and their management. Orbital exenteration was performed on 119 orbits of 119 patients over a 14-year period. The mean age was 48.9 years (range 1-82 years). The indications were malignancies in 90.7 % (108/119), while 9.3 % (11/119) of cases were exenterated for non-malignant indications. Among the malignancies, the commonest tissue of origin was conjunctiva, noted in 45.4 % (49/108), followed by eyelids (25.9 %, 28/108), orbit (19.4 %, 21/108), and intraocular tissues (9.3 %, 10/108). The commonest malignancies noted in this series were an extensive ocular surface squamous neoplasia (OSSN) (44.4 %, 48/108) and sebaceous gland carcinoma of eyelids with an orbital involvement (18.5 %, 20/108). Extensive fungal granuloma (mucormycosis-4, aspergillosis-4) was the commonest (81.8 %, 9/11) indication among the non-malignant group. All complications were wound related, and none had a recurrence at a mean follow-up of 12.8 months. Extensive orbital involvement with OSSN and SGC were the commonest indications for exenteration. There is a need of creating awareness among general ophthalmologists in specific geographical regions regarding early diagnosis, standardized protocols of management, and appropriate referral.

Entities:  

Keywords:  Awareness; Exenteration; Malignancy; Ocular surface squamous neoplasia; Orbit; Sebaceous gland carcinoma

Mesh:

Year:  2015        PMID: 26249131     DOI: 10.1007/s10792-015-0111-5

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  20 in total

1.  Experience with eyelid-sparing orbital exenteration: the 2000 Tullos O. Coston Lecture.

Authors:  J A Shields; C L Shields; H Demirci; S G Honavar; A D Singh
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2001-09       Impact factor: 1.746

2.  Evaluation of 48 cases of orbital exenteration.

Authors:  J E Rathbun; C Beard; M H Quickert
Journal:  Am J Ophthalmol       Date:  1971-07-30       Impact factor: 5.258

3.  Indications and surgical techniques for orbital exenteration.

Authors:  R E Kennedy
Journal:  Ophthalmology       Date:  1979-05       Impact factor: 12.079

4.  Orbital exenteration with spontaneous granulation.

Authors:  A M Putterman
Journal:  Arch Ophthalmol       Date:  1986-01

5.  Malignant tumors of the orbit and periorbital structures treated by exenteration.

Authors:  J N Simons; D W Robinson; F W Masters
Journal:  Plast Reconstr Surg       Date:  1966-02       Impact factor: 4.730

Review 6.  Orbital exenteration for advanced periorbital skin cancers: 20 years experience.

Authors:  Reza S Nassab; Sunil S Thomas; Douglas Murray
Journal:  J Plast Reconstr Aesthet Surg       Date:  2007-04-16       Impact factor: 2.740

7.  Orbital exenteration at the Mayo Clinic. 1967-1986.

Authors:  G B Bartley; J A Garrity; R R Waller; J W Henderson; D M Ilstrup
Journal:  Ophthalmology       Date:  1989-04       Impact factor: 12.079

8.  A 20-year series of orbital exenteration.

Authors:  P S Levin; J J Dutton
Journal:  Am J Ophthalmol       Date:  1991-11-15       Impact factor: 5.258

Review 9.  Life expectancy following orbital exenteration.

Authors:  James Chiun Lon Wong; Reshma Thampy; Anne Cook
Journal:  Br J Ophthalmol       Date:  2014-05-30       Impact factor: 4.638

10.  Pattern of orbital exenteration in a tertiary eye care centre in India.

Authors:  Neelam Pushker; Seema Kashyap; Ramamurthy Balasubramanya; Mandeep S Bajaj; Seema Sen; Subhash M Betharia; Supriyo Ghose
Journal:  Clin Exp Ophthalmol       Date:  2004-02       Impact factor: 4.207

View more
  7 in total

1.  Orbital exenteration for advanced periorbital non-melanoma skin cancer: prognostic factors and survival.

Authors:  R C Gerring; C T Ott; J M Curry; Z B Sargi; S T Wester
Journal:  Eye (Lond)       Date:  2016-10-21       Impact factor: 3.775

2.  Clinicodemographic profile and treatment outcome in patients of ocular surface squamous neoplasia.

Authors:  Rachna Meel; Rebika Dhiman; Murugesan Vanathi; Neelam Pushker; Radhika Tandon; Saranya Devi
Journal:  Indian J Ophthalmol       Date:  2017-10       Impact factor: 1.848

Review 3.  Updates on the clinical diagnosis and management of ocular sebaceous carcinoma: a brief review of the literature.

Authors:  Yangfan Xu; Fang Li; Renbing Jia; Xianqun Fan
Journal:  Onco Targets Ther       Date:  2018-06-27       Impact factor: 4.147

4.  Factors related to survival outcomes following orbital exenteration: a retrospective, comparative, case series.

Authors:  Orapan Aryasit; Passorn Preechawai; Chakree Hirunpat; Orasa Horatanaruang; Penny Singha
Journal:  BMC Ophthalmol       Date:  2018-07-28       Impact factor: 2.209

5.  Treatment outcome with interferon alpha 2b in ocular surface squamous neoplasia: Recommendation as primary treatment by peripheral ophthalmologists.

Authors:  Rachna Meel; Rebika Dhiman; Murugesan Vanathi; Seema Sen; Noopur Gupta; Radhika Tandon
Journal:  Oman J Ophthalmol       Date:  2021-02-27

6.  Conjunctival Squamous Cell Carcinoma with Corneal Stromal Invasion in Presumed Pterygia: A Case Series.

Authors:  Pia R Mendoza; Caroline M Craven; Matthew H Ip; Matthew W Wilson; Minas T Coroneo; Hans E Grossniklaus
Journal:  Ocul Oncol Pathol       Date:  2018-01-19

7.  Complex reconstruction of the orbitofrontal regions using three regional flaps after orbital exenteration for the treatment of basal cell carcinoma.

Authors:  Cătălin Gheorghe Bejinariu; Christiana Diana Maria Dragosloveanu; Silviu Adrian Marinescu
Journal:  Rom J Ophthalmol       Date:  2020 Jan-Mar
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.